Beta 2 adrenergic receptor polymorphisms, at codons 16 and 27, and bronchodilator responses in adult Venezuelan asthmatic patients

Larocca, N.E.; Moreno, Dolores; Garmendia, Jenny V.; Velasquez, Olga; Martin-Rojo, Joana; Tálamo, Carlos; García, A. Nieto; Sanctis, Juan B. De

doi:10.5507/bp.2012.084

Cited by 13 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The genotype distribution of rs2073838 in both groups did not differ significantly from the distribution in normal populations studied in previous literatures such as Plenge et al, (2005) study on north American and Sweden populations (Plenge et al, 2005). For rs3792876, the distribution in responders goes with that in previous studies while in non-responders the distribution differs significantly from normal populations (Hou et al, 201;Jaruskova et al, 2017;Angelini et al, 2013;De Ridder et al, 2007;Barton et al, 2005;Shahidi and Fitzgerald, 2010;Koskela et al, 2006;Poon et la., 2012;Larocca et al, 2013;Newman et al, 2005;Charan and Biswas, 2013;Heffler et al, 2016;Hegewald et al, 2012;Dunn et al, 2015;Ahmad and Singh, 2010;Chiappori et al, 2012;Plenge et al, 2005;. Finally, none of the studied genotypes was associated with gender, age of onset, positive family history, history of atopy or asthma severity.…”

Section: Discussionmentioning

confidence: 88%

“…The paper printout of the volumetime and flow-volume displays were subjected to the acceptability criteria of the American Thoracic Society (ATS); FEV1, FEV1/FVC ratio, post-bronchodilator FEV1were recorded for each patient. A response was considered positive when a change in FEV1 ≥ 12% and 200 mL after administration of one to two buffs (200-400µg) of salbutamol (Larocca et al, 2013). The test was performed by qualified staff members in the chest clinic under the supervision of the fourth author.…”

Section: Bronchodilator Reversibility Testingmentioning

confidence: 99%

See 1 more Smart Citation

The Role of SLC22A4 Gene Polymorphisms in the Response to Salbutamol in Asthmatic Patients

Ahmed¹,

Said²,

Shahaway³

et al. 2019

American Journal of Immunology

View full text Add to dashboard Cite

Response to Bronchodilators is influenced by many factors including genetics. To evaluate the influence of SLC22A4 gene polymorphisms (rs3792876 and rs2073838) on the response to inhaled salbutamol in asthmatic patients, bronchodilator response was assessed in 180 bronchial asthma patients via measuring changes of the Forced Expiratory Volume in one second (FEV1) after the administration of inhaled salbutamol and genotyping for rs3792876 and rs2073838 was carried out using real-time polymerase chain reaction. Frequencies of genotypes were compared in between responders and non-responders. The frequency of rs2073838 genotypes showed no significant differences. On the other hand, the recessive genotype of rs3792876 occurred more frequently among the non-responding patients P = 0.01, 95% confidence interval (1.2-9.5). The homozygous form of rs3792876 can influence the absorption of inhaled bronchodilator (Salbutamol), although, replication studies on this point are recommended.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Bronchodilator Reversibility Testingmentioning

confidence: 99%

The Role of SLC22A4 Gene Polymorphisms in the Response to Salbutamol in Asthmatic Patients

Ahmed¹,

Said²,

Shahaway³

et al. 2019

American Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…These in vitro studies could explain the mechanisms of these polymorphisms, in particular a possibility of change in function of β-2 adrenergic receptors which has since been corroborated by other studies [18-22]. However, there are also multiple studies that have showed conflicting results about associations between responses due to albuterol and these polymorphisms, with some showing better response in patients with Gly-16 and others showing no associations with either of these two SNPs [23-29].…”

Section: Introductionmentioning

confidence: 60%

The Influence of Beta-2 Adrenergic Receptor Gene Polymorphisms on Albuterol Therapy for Patients With Asthma: Protocol for a Systematic Review and Meta-Analysis

Hikino¹,

Kobayashi²,

Ota³

et al. 2019

JMIR Res Protoc

View full text Add to dashboard Cite

BackgroundAlbuterol is one of the most frequently used medications in clinical practice and seeing varying responses to albuterol between individuals is not uncommon. Multiple studies have been conducted to investigate the associations of differing responses due to albuterol, particularly with regards to the two nonsynonymous single nucleotide polymorphisms (SNPs) at positions 16 (Arg16Gly: substitution of arginine to glycine at position 16; rs1042713) and 27 (Glu27Gln: substitution of glutamic acid to glutamine at position 27; rs1042714) on the β-2 adrenergic receptor (ADRB2) gene. However, the directions of the correlations are conflicting.ObjectiveThe objective of this systematic review and meta-analysis is to assess the effect of the two SNPs on the ADRB2 gene, in terms of the responses that present in asthmatic patients shortly after albuterol inhalation.MethodsThe primary outcome of this work is a detailed study of the associations of the two SNPs in the ADRB2 gene with treatment response and lung function testing shortly after administration of albuterol to asthmatic patients. A comprehensive literature search, using the OVID platform, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, will be conducted by a specialized librarian without language restrictions. We will include both prospective and retrospective original observational studies, and we will exclude nonhuman or in vitro studies. All abstracts will be reviewed by two authors who will also individually perform data extraction from each eligible study. Any arising disagreements will be resolved through discussion with a third party. Risk of bias for all included studies will be independently assessed using the quality of genetic association studies tool. We will report the systematic review and meta-analysis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. A narrative synthesis of study results or meta-analyses will be undertaken when appropriate.ResultsAt the moment of writing, we have already started the preliminary literature search and piloting of the study selection process. The anticipated completion date is September 30, 2019.ConclusionsOur systematic review and meta-analysis aims to clarify the current evidence of associations between the two nonsynonymous SNPs in the ADRB2 gene and the responses that present in asthmatic patients shortly after albuterol inhalation. If positive correlations are found, this knowledge may be used to improve personalized pharmacotherapy of albuterol use.Trial RegistrationPROSPERO CRD42019074554; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=74554International Registered Report Identifier (IRRID)PRR1-10.2196/14759

show abstract

“…Our and most other previous studies on the genetic determinants of tolerance to beta2-agonists have focused on the Arg-Gly polymorphic site at codon 16 which seems to have a more important role in beta2-AR desensitisation, compared to the other polymorphic sites at codon 27 (GlnGlu) [11,13,30]. However a study of asthmatics children with and without nocturnal asthma highlighted an association between beta2-AR 27 polymorphism and response to terbutaline nebulizer [31], whereas Carroll et al in a pooled cohort of 104 children admitted to the intensive care unit (ICU) with a severe asthma exacerbation found that those with the ArgGly16-GlnGln27 haplotype of the beta2-AR were four times more likely to be intubated and mechanically ventilated so showing that also genetic variation at codon 27 can influence the development of a more severe asthma phenotype during acute exacerbations [32].…”

Section: Discussionmentioning

confidence: 99%

Polymorphism of Beta2-Adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results

et al. 2013

View full text Add to dashboard Cite

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in the literature. The aim of this study was to verify whether homozygous for arginine-16 (ArgArg16) and homozygous for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol. Twenty-nine patients with mild-to-moderate asthma, in stable clinical conditions, underwent genotyping at codon 16 of the beta2-AR by RFLP-PCR assay. The effects of a 4-week monotherapy with formoterol (12 g BID) were tested on the peak expiratory flow (PEF) variability and the forced expiratory volume in 1 sec (FEV1) slope of the dose-response curve to salbutamol. Variability in PEF significantly increased during the 4-week treatment period in 14 patients with GlyGly16, but not in 15 patients with ArgArg16 and ArgGly16 ( = 0.032). The FEV1 slope of the dose-response curve to salbutamol decreased after the 4-week treatment period in GlyGly16, but not in pooled ArgArg16 and ArgGly16 patients. This study provides preliminary evidence that tolerance to formoterol develops more frequently in asthmatics with GlyGly16 genotype. If confirmed in a larger population, this finding might be useful in choosing the bronchodilator therapy on the basis of genetic polymorphism of the beta2-AR.

show abstract

Beta 2 adrenergic receptor polymorphisms, at codons 16 and 27, and bronchodilator responses in adult Venezuelan asthmatic patients

Cited by 13 publications

References 26 publications

The Role of SLC22A4 Gene Polymorphisms in the Response to Salbutamol in Asthmatic Patients

The Role of SLC22A4 Gene Polymorphisms in the Response to Salbutamol in Asthmatic Patients

The Influence of Beta-2 Adrenergic Receptor Gene Polymorphisms on Albuterol Therapy for Patients With Asthma: Protocol for a Systematic Review and Meta-Analysis

Polymorphism of Beta2-Adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results

Contact Info

Product

Resources

About